On 12 Nov 2026 Waters Corporation closed at $462.20, +21.7% this year; market cap $45.60bn, P/E 464.2.
Health Care · Life Sciences Tools & Services · NYSE · United States
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
| Market cap | $45.60bn |
| P/E (trailing) | 464.2 |
| EPS (TTM) | $1.00 |
| Beta | 1.15 |
| Dividend | $0.00 |
| Dividend yield | 0.00% |
| Ex-dividend date | 26 Nov 1996 |
| Latest report | 3 Nov 2026 |
| Next earnings | 2 Feb 2027 |
| YTD | +21.7% |
| 1Y | +19.3% |
| 3Y | +22.6% |
| 5Y | +5.3% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $3.17bn | $642.63m | $539.81m |
| 2024 | $2.96bn | $637.83m | $619.64m |
| 2023 | $2.96bn | $642.23m | $442.18m |
| 2022 | $2.97bn | $707.75m | $428.20m |
| 2021 | $2.79bn | $692.84m | $579.01m |
Base value $1,388.66 (+200.4% vs price); 1 of 1 methods above the price. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.